COMPARATIVE INCOME STATEMENT		3rd Qtr Ending: 05/31/2004				9 Months Ending: 05/31/2004
		Amounts in Millions		Favorable/ Unfavorable		Amounts in Millions		Favorable/ Unfavorable
PRELIMINARY		This Year	Last Year	Amount	Pct	This Year	Last Year	Amount	Pct
Net Sales		9,578.5	8,328.0	1,250.5	15.0%	28,081.5	24,259.0	3,822.5	15.8%
Costs and Deductions
	Cost of Sales	7,000.7	6,098.0	-902.7	-14.8%	20,498.0	17,685.2	-2,812.8	-15.9%
	Selling, Occupancy & Admin	2,033.1	1,769.3	-263.8	-14.9%	5,956.8	5,167.2	-789.6	-15.3%
Operating Income		544.7	460.7	84.0	18.2%	1,626.7	1,406.6	220.1	15.6%
	Net Other, Income(Expense)[1][2]	6.6	15.0	-8.4	-56.0%	26.1	36.9	-10.8	-29.3%
Earnings Before Taxes		551.3	475.7	75.6	15.9%	1,652.8	1,443.5	209.3	14.5%
	Income Taxes	206.7	179.6	-27.1	-15.1%	619.8	544.9	-74.9	-13.7%
Earnings After Taxes		344.6	296.1	48.5	16.4%	1,033.0	898.6	134.4	15.0%
[1]	Included: 1st Qtr-2003, Two drug antitrust litigation settlements totaling $16.7; 2nd, 3rd & 4th Qtr-2003, Drug antitrust litigation settlement of$0.3, $12.0, and $0.6
[2]	Included: 2nd Qtr-2004, two drug antitrust litigation settlements totaling of $12.7; 3rd Qtr, Drug antitrust settlement of $3.0
Earnings Per Share - Basic		$ 0.34	$ 0.29	$ 0.05	17.2%	$ 1.01	$ 0.88	$ 0.13	14.8%
	Before Drug Litigation	$ 0.33	$ 0.28	$ 0.05	17.9%	$ 1.00	$ 0.86	$ 0.14	16.3%
Earnings Per Share - Diluted		$ 0.33	$ 0.29	$ 0.04	13.8%	$ 1.00	$ 0.87	$ 0.13	14.9%
	Before Drug Litigation	$ 0.33	$ 0.28	$ 0.05	17.9%	$ 0.99	$ 0.85	$ 0.14	16.5%
Dividends Per Share		$ 0.04313	$ 0.03750	$ 0.00563	15.0%	$ 0.12938	$ 0.11250	$ 0.01688	15.0%
Weighted Avg Shares Basic		1,023.3	1,024.9			1,024.2	1,024.9
Weighted Avg Shares Diluted		1,030.3	1,031.1			1,031.6	1,031.6
Return on Avg Shareholder Equity [1][2]		4.4%	4.3%			13.5%	13.4%
Effective Income Tax Rate		37.50%	37.75%			37.50%	37.75%
LIFO Charge/(Credit)		12.7	9.0			55.2	55.7

INCOME STATEMENT SUMMARY		1st Qtr Ending: 11/30/2003			2nd Qtr Ending: 02/29/2004			6 Months Ending: 02/29/2004			3rd Qtr Ending: 05/31/2004			9 Months Ending: 05/31/2004
		% of	% to Sales		% of	% to Sales		% of	% to Sales		% of	% to Sales		% of	% to Sales
PRELIMINARY		Chg	2003	2002	Chg	2004	2003	Chg	2004	2003	Chg	2004	2003	Chg	2004	2003
Net Sales		16.5%	100.00	100.00	15.8%	100.00	100.00	16.1%	100.00	100.00	15.0%	100.00	100.00	15.8%	100.00	100.00
Costs and Deductions
	Cost of Sales	17.0%	73.63	73.34	16.0%	72.34	72.20	16.5%	72.94	72.73	14.8%	73.08	73.22	15.9%	73.00	72.90
	Selling, Occupancy & Admin	15.3%	21.73	21.95	15.6%	20.74	20.78	15.5%	21.21	21.33	14.9%	21.23	21.25	15.3%	21.21	21.30
	Sub-Total	16.6%	95.36	95.29	15.9%	93.08	92.98	16.3%	94.15	94.06	14.8%	94.31	94.47	15.8%	94.21	94.20
Earnings Before Other Income		14.8%	4.64	4.71	14.1%	6.92	7.02	14.4%	5.85	5.94	18.2%	5.69	5.53	15.6%	5.79	5.80
	Net Other, Income (Expense) [1][2]	-85.5%	0.04	0.26	542.3%	0.17	0.03	-11.0%	0.10	0.13	-56.0%	0.07	0.18	-29.3%	0.10	0.15
Earnings Before Taxes		9.6%	4.68	4.97	16.4%	7.09	7.05	13.8%	5.95	6.07	15.9%	5.76	5.71	14.5%	5.89	5.95
	Effective Income Tax Rate		37.50%	37.75%		37.50%	37.75%		37.50%	37.75%		37.50%	37.75%		37.50%	37.75%
Earnings After Taxes		10.1%	2.92	3.09	16.9%	4.43	4.39	14.3%	3.72	3.78	16.4%	3.60	3.56	15.0%	3.68	3.70
[1]	Included: 1st Qtr-2003, Two drug antitrust litigation settlements totaling $16.7; 2nd, 3rd & 4th Qtr-2003, Drug antitrust litigation settlement of $0.3, $12.0, and $0.6
[2]	Included: 2nd Qtr-2004, two drug antitrust litigation settlements totaling of $12.7; 3rd Qtr, Drug antitrust settlement of $3.0

								PRELIMINARY									CONTINUING OPERATIONS
	Total	Percent Change in Sales				Key Operating Ratios			Other Items			Company Income and Return on Sales
	Company	Total	Drug Stores			Gross		Op	Net	Other		Pre-Tax	Tax	Income After Taxes
Period	Sales	Co	Total	Comp	Est	Profit	SGA	Income	Interest	Income	% Sales	% Sales	Rate	Amount	% Sales	% Chg
	Amounts in Millions															Other Income: Antitrust Litigation Settlements
00-Q1	4,823.2	20.1	20.1	13.5	11.7	26.38	22.02	4.36	1.1	0.0	0.02	4.38	39.50	127.8	2.65	23.0
00-Q2	5,608.8	19.6	19.6	12.2	10.1	27.51	20.54	6.97	1.1	0.0	0.02	6.99	39.10	238.9	4.26	19.3
00-Q3	5,394.1	18.0	18.0	10.6	7.9	26.90	21.10	5.80	2.1	0.0	0.04	5.84	38.52	193.6	3.59	21.6
00-Q4	5,380.8	18.0	18.0	10.8	7.9	27.40	21.64	5.76	1.4	33.5	0.65	6.41	37.18	216.6	4.03	34.9
2000	21,206.9	18.9	18.9	11.7	9.6	27.07	21.30	5.77	5.7	33.5	0.19	5.96	38.50	776.9	3.66	24.5
	Amounts in Millions															Other Income: Antitrust Litigation Settlements
01-Q1	5,614.2	16.4	16.4	10.8	9.1	26.51	21.92	4.59	0.0	0.0	0.00	4.59	38.51	158.4	2.82	23.9
01-Q2	6,429.0	14.6	14.6	8.7	6.6	27.55	20.44	7.11	0.8	22.1	0.35	7.46	38.12	296.9	4.62	24.3
01-Q3	6,296.2	16.7	16.7	11.3	8.8	26.23	20.74	5.49	0.0	0.0	0.00	5.49	38.23	213.4	3.39	10.2
01-Q4	6,283.6	16.8	16.8	11.2	8.4	26.47	21.09	5.38	1.5	0.0	0.03	5.41	36.17	216.9	3.45	0.1
2001	24,623.0	16.1	16.1	10.5	8.4	26.70	21.02	5.68	2.3	22.1	0.10	5.78	37.75	885.6	3.60	14.0
	Amounts in Millions															Other Income: Antitrust Litigation Settlements
02-Q1	6,559.4	16.8	16.8	10.7	8.7	25.88	21.43	4.45	1.2	5.5	0.10	4.55	37.75	185.9	2.83	17.4
02-Q2	7,488.5	16.5	16.5	10.2	7.8	27.16	20.17	6.99	1.2	0.0	0.02	7.01	37.75	326.6	4.36	10.0
02-Q3	7,397.9	17.5	17.5	11.5	8.7	26.19	20.59	5.60	1.9	0.0	0.02	5.62	37.75	259.0	3.50	21.4
02-Q4	7,235.3	15.1	15.2	9.4	6.5	26.76	21.30	5.46	2.6	0.7	0.04	5.50	37.75	247.7	3.42	14.2
2002	28,681.1	16.5	16.5	10.5	8.1	26.51	20.85	5.66	6.9	6.2	0.05	5.71	37.75	1,019.2	3.55	15.1
	Amounts in Millions															Other Income: Antitrust Litigation Settlements
03-Q1	7,484.9	14.1	14.1	8.6	6.9	26.66	21.95	4.71	2.6	16.7	0.26	4.97	37.75	231.6	3.09	24.6
03-Q2	8,446.1	12.8	12.8	7.7	5.8	27.80	20.78	7.02	2.3	0.3	0.03	7.05	37.75	370.9	4.39	13.6
03-Q3	8,328.0	12.6	12.6	8.2	6.1	26.78	21.25	5.53	3.0	12.0	0.18	5.71	37.75	296.1	3.56	14.3
03-Q4	8,246.4	14.0	14.0	9.9	7.5	26.99	21.63	5.36	2.9	0.6	0.04	5.40	37.75	277.1	3.36	11.9
2003	32,505.4	13.3	13.3	8.6	6.6	27.07	21.38	5.69	10.8	29.6	0.12	5.81	37.75	1,175.7	3.62	15.4
	Amounts in Millions															Other Income: Antitrust Litigation Settlements
04-Q1	8,720.8	16.5	16.5	11.9	10.4	26.37	21.73	4.64	2.8	0.0	0.04	4.68	37.50	254.9	2.92	10.1
04-Q2	9,782.2	15.8	15.8	11.5	9.9	27.66	20.74	6.92	4.0	12.7	0.17	7.09	37.50	433.5	4.43	16.9
04-Q3	9,578.5	15.0	15.0	10.4	8.7	26.92	21.23	5.69	3.6	3.0	0.07	5.76	37.50	344.6	3.60	16.4
04-Q4
2004	28,081.5	15.8	15.8	11.3	9.7	27.00	21.21	5.79	10.4	15.7	0.10	5.89	37.50	1,033.0	3.68	15.0

														STORE COUNT AND MONTHLY SALES INCREASES
									PRELIMINARY
Number of Drug Stores
					Six				Nine				Total
		1st Qtr	2nd Qtr		Mos		3rd Qtr		Mos		4th Qtr		Year
1999-00	Start of Period	2,821	2,894		2,821		2,967		2,821		3,051		2,821
	Opened	94	103		197		106		303		159		462
	Relocation	-19	-25		-44		-20		-64		-43		-107
	Closed	-2	-5		-7		-2		-9		-2		-11
	End of Period	2,894	2,967		2,967		3,051		3,051		3,165		3,165
2000-01	Start of Period	3,165	3,260		3,165		3,343		3,165		3,424		3,165
	Opened	126	112		238		105		343		131		474
	Relocation	-30	-26		-56		-19		-75		-30		-105
	Closed	-1	-3		-4		-5		-9		-5		-14
	End of Period	3,260	3,343		3,343		3,424		3,424		3,520		3,520
2001-02	Start of Period	3,520	3,623		3,520		3,678		3,520		3,766		3,520
	Opened	134	76		210		109		319		152		471
	Relocation	-29	-14		-43		-19		-62		-31		-93
	Closed	-2	-7		-9		-2		-11		-4		-15
	End of Period	3,623	3,678		3,678		3,766		3,766		3,883		3,883
2002-03	Start of Period	3,883	3,954		3,883		3,998		3,883		4,050		3,883
	Opened	92	62		154		67		221		209		430
	Relocation	-20	-11		-31		-13		-44		-31		-75
	Closed	-1	-7		-8		-2		-10		-1		-11
	End of Period	3,954	3,998		3,998		4,050		4,050		4,227		4,227
2003-04	Start of Period	4,227	4,291		4,227		4,336		4,227
	Opened	85	55		140		88		228
	Relocation	-20	-6		-26		-9		-35
	Closed	-1	-4		-5		-1		-6
	End of Period	4,291	4,336		4,336		4,414		4,414
Monthly Sales Percent Increases
		Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Year
	1999-00	19.6	18.5	22.2	22.2	16.7	19.0	15.5	17.7	20.8	17.9	16.5	19.6	18.9
	2000-01	16.1	17.2	15.8	8.9	21.8	15.1	17.3	16.9	16.0	14.8	18.2	17.3	16.1
	2001-02	15.0	19.1	16.2	14.1	17.3	18.6	18.5	16.7	17.4	15.5	16.9	16.5	16.5
	2002-03	17.2	13.3	12.2	13.4	12.7	15.9	10.2	15.2	12.4	14.4	13.7	13.8	13.3
	2003-04	17.8	16.6	15.3	17.7	13.2	16.3	17.4	15.1	12.6				15.8

						PRELIMINARY
INTERIM HIGHLIGHTS				Six		Nine		Total
		1st Qtr	2nd Qtr	Mos	3rd Qtr	Mos	4th Qtr	Year
Total Sales	1999-00	4,823.2	5,608.8	10,432.0	5,394.1	15,826.1	5,380.8	21,206.9
(In Millions)	2000-01	5,614.2	6,429.0	12,043.2	6,296.2	18,339.4	6,283.6	24,623.0
	2001-02	6,559.4	7,488.5	14,047.9	7,397.9	21,445.8	7,235.3	28,681.1
	2002-03	7,484.9	8,446.1	15,931.0	8,328.0	24,259.0	8,246.4	32,505.4
	2003-04	8,720.8	9,782.2	18,503.0	9,578.5	28,081.5
% of Increase	1999-00	20.1%	19.6%	19.8%	18.0%	19.2%	18.0%	18.9%
	2000-01	16.4%	14.6%	15.4%	16.7%	15.9%	16.8%	16.1%
	2001-02	16.8%	16.5%	16.6%	17.5%	16.9%	15.1%	16.5%
	2002-03	14.1%	12.8%	13.4%	12.6%	13.1%	14.0%	13.3%
	2003-04	16.5%	15.8%	16.1%	15.0%	15.8%
Net Income	1999-00	127.8	238.9	366.7	193.6	560.3	216.6	776.9
[1][2][3]	2000-01	158.4	296.9	455.3	213.4	668.7	216.9	885.6
(In Millions)	2001-02	185.9	326.6	512.5	259.0	771.5	247.7	1,019.2
	2002-03	231.6	370.9	602.5	296.1	898.6	277.1	1,175.7
	2003-04	254.9	433.5	688.4	344.6	1,033.0
% of Increase	1999-00	23.0%	19.3%	20.5%	21.6%	20.9%	34.9%	24.5%
[1][2][3]	2000-01	23.9%	24.3%	24.2%	10.2%	19.3%	0.1%	14.0%
	2001-02	17.4%	10.0%	12.6%	21.4%	15.4%	14.2%	15.1%
	2002-03	24.6%	13.6%	17.6%	14.3%	16.5%	11.9%	15.4%
	2003-04	10.1%	16.9%	14.3%	16.4%	15.0%
Diluted [1][2][3]		Earnings Per Share Data Adjusted For Splits
Earnings Per Share	1999-00	$ 0.13	$ 0.23	$ 0.36	$ 0.19	$ 0.55	$ 0.21	$ 0.76
Before Drug Litigation		$ 0.13	$ 0.23	$ 0.36	$ 0.19	$ 0.55	$ 0.19	$ 0.74
	2000-01	$ 0.15	$ 0.29	$ 0.44	$ 0.21	$ 0.65	$ 0.21	$ 0.86
Before Drug Litigation		$ 0.15	$ 0.28	$ 0.43	$ 0.21	$ 0.64	$ 0.21	$ 0.85
	2001-02	$ 0.18	$ 0.32	$ 0.50	$ 0.25	$ 0.75	$ 0.24	$ 0.99
Before Drug Litigation		$ 0.18	$ 0.32	$ 0.49	$ 0.25	$ 0.74	$ 0.24	$ 0.98
	2002-03	$ 0.22	$ 0.36	$ 0.58	$ 0.29	$ 0.87	$ 0.27	$ 1.14
Before Drug Litigation		$ 0.21	$ 0.36	$ 0.57	$ 0.28	$ 0.85	$ 0.27	$ 1.12
	2003-04	$ 0.25	$ 0.42	$ 0.67	$ 0.33	$ 1.00
Before Drug Litigation		$ 0.25	$ 0.41	$ 0.66	$ 0.33	$ 0.99
[1] Income settlements of drug antitrust litigation: 4th Qtr-2000: $33.5; 2nd Qtr-2001: $22.1; 1st Qtr-2002: $5.5; 4th Qtr-2002: $0.7
[2] Income settlements of drug two antitrust litigation: 1st Qtr-2003: $16.7; 2nd, 3rd, $ 4th Qtr-2003, Drug antitrust litigation settlement of $0.3, $12.0, $0.6.
[3] 2nd Qtr-2004, two drug antitrust litigation settlements totaling of $12.7; 3rd Qtr, Drug antitrust settlement of $3.0

							PRELIMINARY
CONSOLIDATED BALANCE SHEET			May 31					May 31
			2004	2003				2004	2003
Current Assets					Current Liabilities
	Cash & Equivalents		1,577.0	854.4		Short Term Borrowings		0.0	0.0
	Accounts Receivable, Less Allowance		1,298.3	1,007.7		Trade Accounts Payable		2,277.1	1,955.8
	Inventories		4,359.8	4,020.1		Other Current Liabilities		1,407.4	1,128.3
	Other Current Assets		152.6	145.4		Income Taxes		139.4	140.2
		Total Current Assets	7,387.7	6,027.6			Total Current Liabilities	3,823.9	3,224.3
Non-Current Assets					Non-Current Liabilities
	Property and Equipment		5,255.4	4,822.4		Deferred Income Taxes		279.3	215.7
	Other Non-Current Assets		111.0	109.5		Other Non-Current Liabilities		645.9	549.4
		Total Non-Current Assets	5,366.4	4,931.9			Total Non-Current Liabilities	925.2	765.1
					Total Liabilities			4,749.1	3,989.4
					Shareholder Equity			8,005.0	6,970.1
Total Assets			12,754.1	10,959.5	Total Liabilities & Equity			12,754.1	10,959.5
STATEMENT OF CASH FLOWS			May 31					May 31
			2004	2003				2004	2003
Cash Flows From Operating Activities					Provided/(Used) by Invest & Finance
	Net Income		1,033.0	898.6		Property, Plant & Equipment		(630.9)	(573.0)
	Depreciation & Amortization		288.2	252.8		Employee Stock Plan Proceeds		101.3	60.3
	Inc Tax Savings From Employee Stock Plans		25.6	20.9		Property & Equip Disp and Other		16.1	68.8
	Deferred Income Taxes		28.0	18.8		Cash Dividends		(132.6)	(114.0)
	Other		25.8	11.1		Stock Purchases		(184.6)	(149.2)
						Changes in Short Term Borrowings		0.0	0.0
						Net Proceeds from Corp Owned Life Ins		8.6	9.1
						Other		(11.3)	(3.1)
Changes in Current Assets & Liabilities:
	Inventory		(157.2)	(374.9)
	Trade Accounts Payable		200.0	119.3
	Accrued Expenses & Liabilities		149.4	74.2
	Income Taxes		33.5	39.3	Provided/(Used) by Invest & Finance			(833.4)	(701.1)
	Accounts Receivable		(300.3)	(18.8)
	Insurance Reserve		84.5	72.6		Changes In Cash & Equivalents		559.9	404.5
	Other Current Assets		(17.2)	(8.3)		Beginning Cash & Equivalents		1,017.1	449.9
Provided/(Used) for Operating Activities			1,393.3	1,105.6	Cash & Equivalents at End of Period			1,577.0	854.4